Overview
Dr. Schackman is the Director of CHERISH – The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV - a multi-institutional Center of Excellence, funded by the National Institute on Drug Abuse (P30DA040500). CHERISH is a collaboration among researchers at Weill Cornell Medicine, Boston Medical Center, the University of Pennsylvania Leonard Davis Institute of Health Economics, and the University of Miami Miller School of Medicine. Dr. Schackman is the Saul P. Steinberg Distinguished Professor of Healthcare Policy & Research at Weill Cornell, where he conducts economic evaluations of the comparative effectiveness of health interventions alongside clinical trials and cohort studies, cost-effectiveness and comparative effectiveness simulation modeling studies, and implementation science studies—particularly relating to treatment of infectious diseases and substance use disorders. His current research includes economic evaluations of HIV and hepatitis C screening and treatment in substance use treatment settings, and economic evaluations of treatments for opioid use disorder.
Highlights
- 1
- 2Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021
- 3Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025
Publications
Funding
Active
8 grants- Co-IColumbia University-Weill Cornell Medicine CFAR (CU-WCM CFAR)National Institute of Allergy and Infectious Diseases · 2026–2031 · via Columbia University
- PIHealth Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge TranslationNational Institute on Drug Abuse · 2015–2030· 6 renewalsP30DA040500-12
- Co-IReversing Overdose Epidemics through Simulation, Collaboration, and Unified Efforts (RESCUE)National Institute on Drug Abuse · 2024–2028 · via University of MinnesotaR33DA062346-01
- PIHEAL Data2Action Modeling and Economic Resource CenterNational Institute on Drug Abuse · 2022–2027U24DA057650-05
- Sub-PIMiami Dade County ASsessment of Phylogenics to Improve Resource Equity: MD ASPIRENational Institute of Mental Health · 2022–2027 · via University of California, San DiegoR01MH132151-05
- Sub-PIAccelerating Implementation of Multilevel-strategies to Advance Long Acting Injectables for Underserved Populations (The ALAI UP Project)Health Resources and Services Administration · 2024–2026 · via Columbia University6 U1SHA46532-03-01
- Co-ICDC Overdose Data to Action: LocalFund for Public Health in New York, Inc. · 2023–2026ContractSA 241817-01
- Co-IDisparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods StudyNational Institute of Diabetes and Digestive and Kidney Diseases · 2020–2026
Completed grants (38)
- Co-IReducing Post-Hospital Mortality in HIV-Infected Adults in TanzaniaNational Institute of Mental Health · 2018–2025R01MH118107-01
- Sub-PICHASE: An Innovative County-Level Public Health Response to the Opioid Epidemic in New York StateNational Institute on Drug Abuse · 2019–2025 · via Columbia UniversityUM1DA049415-05
- PIDAT-18-06 Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)National Institute on Drug Abuse · 2019–2025U01DA047408-05
- Co-IHealth and Economic Outcomes of Treatment with Extended-Release Naltrexone Among Pre-Release Prisoners with Opioid Use DisorderNational Institute on Drug Abuse · 2019–2025
- PISimulation Modeling To Support The Public Health Response To The Opioid Crisis In North AmericaNational Institute on Drug Abuse · 2021–2024R13DA052198-04
- PIDAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service ProgramsNational Institute on Drug Abuse · 2009–2024· 5 renewals
- MPIA Multi-Site Multi-Setting RCT of Integrated HIV Prevention and HCV Care for PWIDNational Institute on Drug Abuse · 2017–2024 · via Columbia UniversityR01DA045713-05
- MPIImpact of Jail-Based Methadone on Overdose, Recidivism, HIV, and Health Outcomes and Costs in New York City, 2011-2017National Institute on Drug Abuse · 2018–2024 · via New York University School of Medicine (Grossman)R01DA045042-04
- Sub-PIAddiction Health Services Research ConferenceNational Institute on Drug Abuse · 2023–2024 · via University of WisconsinR13DA058506-01
- Sub-PIHEALing Communities Study: Data Coordinating CenterNational Institute on Drug Abuse · 2019–2024 · via RTI International· 2 renewalsUM1DA049394-01
- Sub-PIA pragmatic trial of two strategies for implementing an effective eHealth HIV prevention programNational Institute of Mental Health · 2018–2023 · via Northwestern UniversityR01MH118213-03
- MPIResearching Effective Strategies to Prevent Opioid Death (RESPOND)National Institute on Drug Abuse · 2018–2023 · via Boston Medical Center (Corporation)R01DA046527-05
- Co-IExpanding FDA's Opioids Systems Model to Enable Economic Evaluations and Outcome Analyses of National Opioid PoliciesUnited States Food & Drug Administration · 2020–2022 · via The General Hospital Corporation (dba Massachusetts General Hospital)U01FD007064-01
- Co-IFANMI: Community Cohort Care for HIV-infected Adolescent Girls in HaitiEunice Kennedy Shriver National Institute of Child Health and Human Development · 2017–2022R01HD091935-04
- Sub-PIA Cluster RCT to Increase HIV Testing in Substance Use Treatment ProgramsNational Institute on Drug Abuse · 2016–2022 · via Columbia UniversityR01DA043130-05
- Co-IPRimary care Opioid Use Disorders Treatment (PROUD) TrialNational Institute on Drug Abuse · 2019–2022 · via Kaiser Foundation Research Institute
- Sub-PIEvaluation of Community-based Drug User Health Hubs to Reduce Opioid Overdoses in NY StateCenters for Disease Control and Prevention · 2018–2022 · via Health Research INC (Center for Community Health)
- Sub-PILocalized Economic Modeling to Optimize Public Health Strategies for HIV treatment and PreventionNational Institute on Drug Abuse · 2016–2021 · via Simon Fraser UniversityR01DA041747-05
- PIEconomic Evaluation of Medication-Assisted Substance Abuse TreatmentNational Institute on Drug Abuse · 2014–2020R01DA035808-04
- KPWeill Cornell Medical College-New Jersey Medical School Clinical Trials UnitNational Institute of Allergy and Infectious Diseases · 2013–2020UM1AI069419-12
- Co-IConditional M. Tuberculosis Knockdown Mutants for TB Drug DevelopmentBill & Melinda Gates Foundation · 2017–2020BMGF OPP1024065
- PIEnhanced Access to HIV Care for Drug Users in San Juan, Puerto RicoNational Institute on Drug Abuse · 2013–2020R01DA035280-05
- Sub-PIHealthCall: Enhancing Brief Intervention for HIV Primary Care Alchohol DependenceNational Institute on Alcohol Abuse and Alcoholism · 2014–2019 · via Research Foundation for Mental Hygiene, Inc.R01AA023163-05
- MPIThe Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkNational Institute on Drug Abuse · 2015–2019 · via University of MiamiUG1DA013720-19
- PIConsulting Agreement Amendment (Term Extension for Zack Rosen)OneGreenOak, LLC · 2018–2019ContractSA 184128-01
- PIConsulting Agreement Amendment No. 1 (Term extension)John Mordecai · 2018–2019ContractSA 184127-01
- Sub-PICost-Effectiveness of Preventing HIV ComplicationsNational Institute of Allergy and Infectious Diseases · 2010–2018 · via The General Hospital Corporation (dba Massachusetts General Hospital)· 2 renewalsR37AI042006-20
- Sub-PIProject INSPIRE-NYCCenters for Medicare & Medicaid Services · 2014–2018 · via Fund for Public Health in New York, Inc.5 C1 CMS331330-04
- PISupervised Injection Facility Feasibility StudyFund for Public Health in New York, Inc. · 2017–2017ContractFPHNY SA
- Sub-PIIntensive Models of HCV Care for Injection Drug UsersNational Institute on Drug Abuse · 2012–2017 · via Yeshiva UniversityR01DA034086-06
- Sub-PISimulation Modeling to Improve HIV/HCV Screening, Treatment and CareNational Institute on Drug Abuse · 2012–2016 · via The General Hospital Corporation (dba Massachusetts General Hospital)R01DA031059-04
- PIQuality of Life Outcomes in Prescription and Injection Opioid DependenceNational Institute on Drug Abuse · 2012–2016
- KPIntegrated vs. Separate Care for Hepatitis C, Substance Abuse, and HIV PreventionNational Institute on Drug Abuse · 2010–2015 · via State University of New York Downstate Medical CenterR01DA029512-03
- MPIHPTN 065 HIV Testing Cost AnalysisNational Institutes of Health · 2013–2014 · via Family Health InternationalUM1AI068619-09
- KPHaiti AIDS Research Training: Models to ImplementationFogarty International Center · 2009–2014 · via GHESKIO CentersU2RTW006896-09
- Sub-PIModeling the Impact of HIV Prevention InterventionsNational Institute of Mental Health · 2010–2014 · via Harvard UniversityR01MH087328-04
- Sub-PIPharmacogenomics of HIV TherapyNational Institute of Allergy and Infectious Diseases · 2009–2013 · via Vanderbilt UniversityR01AI077505-05
- PIHCV Treatment Cost-Effectiveness in 3 IDU PopulationsNIDA · 2004–2010 · via NIH RePORTERK01DA017179-05
Clinical research
Completed & closed trials (2)
- PIFeasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service ProgramsWeill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
- PIHEALing Communities StudyResearch Triangle Institute · CLOSED TO ACCRUAL (as of 2023)
News mentions
- New Funding for Health Economics Research on Substance Use Disorder TreatmentsOctober 30, 2025
A team led by Weill Cornell Medicine and University of Miami’s Miller School of Medicine investigators has been awarded a five-year, $4 million grant from the National Institute on Drug Abuse (NIDA) for health economics research.
- Research Highlights Prevention Efforts in Fentanyl OverdosesJanuary 16, 2025
The overwhelming majority of those in New York City who obtained a naloxone kit to counteract opioid overdose had a high need for the drug, according to a new study by Weill Cornell Medicine investigators and the New York City Department of Health and Mental Hygiene.
- Weill Cornell Medicine Awarded NIH Grant to Address Opioid Health CrisisNovember 7, 2022
Weill Cornell Medicine has been awarded a five-year, $8.1 million grant from the National Institutes of Health (NIH) to support economic analysis, simulation modeling and other research approaches to help stem the national opioid epidemic.
- Department of Population Health Sciences Established at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical CenterJuly 22, 2020
Weill Cornell Medicine and NewYork-Presbyterian have realigned the Department of Healthcare Policy and Research to address the intersection of research and practice. The newly named Department of Population Health Sciences, led by distinguished health services researcher, information scientist and leader Dr. Rainu Kaushal, aims to improve the health of populations through data-driven research, innovative technology and novel education programs.
Mentoring
- RYRoger YingMD mentee · Class of 2019
- HZHao ZhangPostdoc
- JMJake MorganResearch
- LSLaura StarbirdResearch
- NJNatrina JohnsonResearch
- RERachel EpsteinResearch
- SGSarah GutkindWCM Affiliate
- XZXiao ZangResearch
External relationships
Other
Simon Fraser University